Concepedia

H. S. Rugo

HS

35

Publications

2.2K

Citations

21

H-Index

1994

Active since

Affiliations

University of California, San Francisco(Current)

UCSF Helen Diller Family Comprehensive Cancer Center

Memorial Sloan Kettering Cancer Center

Dana-Farber Cancer Institute

Samsung Medical Center

H. S. Rugo is an author at University of California, San Francisco specializing in oncology, medicine, and cancer therapeutics.

Top concepts

Publications per year

1994–2023

35

Publications

35

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Sylvia Adams, P. Schmid, H. S. Rugo et al. · Annals of Oncology · 2018 · 756 citations · Full text

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

Matti Aapro, H. S. Rugo, Giada Rizzi et al. · Annals of Oncology · 2014 · 244 citations · Full text

A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).

J. O’Shaughnessy, Lee S. Schwartzberg, Michael Danso et al. · Journal of Clinical Oncology · 2011 · 244 citations

Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130

H. S. Rugo, Sherene Loi, Sylvia Adams et al. · Annals of Oncology · 2019 · 113 citations · Full text

, , +10

LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer

Leisha A. Emens, Sylvia Adams, Carlos H. Barrios et al. · Annals of Oncology · 2020 · 61 citations · Full text

, , +8

Rows per page

1–5 of 35